Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Neo Biopharm ApS
APS
Active
CVR 42875708
Kildegårdsvej 18D
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2021
— employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2024
DKK 206K
-61% vs 2023
EBITDA margin
100.0%
-38% vs 2023
Equity ratio
90.2%
Financial strength
Net profit 2024
DKK 157K
-36% vs 2023
EBITDA — year on year
DKK millions
0M
1M
1M
2M
3M
2M
2022
0M
-100%
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
DKK 206K
-61%
EBITDA
DKK 206K
-38%
Net profit
DKK 157K
-36%
Total assets
DKK 2,5M
-8%
Equity
DKK 2,3M
+7%
Employees
—
—
Company information
Legal name
Neo Biopharm ApS
CVR number
42875708
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
23. november 2021
Share capital
DKK 40.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktion
Company purpose
Selskabets formål er at drive konsulentvirksomhed samt dermed beslægtet virksomhed.
Contact
Address
Kildegårdsvej 18D
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Gentofte
All Denmark companies
Revenue
DKK millions
0M
1M
1M
2M
2M
2M
2022
1M
2023
0M
2024
EBITDA
DKK millions
0M
1M
1M
2M
2M
2M
2022
0M
2023
0M
2024
Income statement
DKK thousands
Item
2022
2023
2024
Revenue
2.458
528
206
Staff expenses
-0
-0
-0
EBITDA
2.358
335
206
Depreciation & amort.
-0
-0
-0
EBIT
2.358
335
206
Net financials
-16
-19
-11
Profit before tax
2.342
316
195
Tax
517
72
38
Net profit
1.825
244
157
Balance sheet
DKK thousands
Item
2022
2023
2024
Total assets
2.593
2.745
2.513
Equity
1.865
2.109
2.266
Long-term debt
0
0
0
Short-term debt
728
637
247
Total debt
728
637
247
Financial ratios
5-year trend
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
2022
2024
Equity ratio
90.2%
This company
38.2%
Market median
+136% vs market
2022
2024
Return on equity
6.9%
This company
18.4%
Market median
-63% vs market
2022
2024
Net profit margin
76.3%
This company
8.1%
Market median
+842% vs market
2022
2024
Asset turnover
0.08×
This company
1.12×
Market median
-93% vs market
2022
2024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
2022
2024
Annual reports & filings
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2021-11-23 – 2022-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Age
Other directorships
JJ
Jakob Juul Rasmussen
Management
Management
2024
—
—
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Maryam Badri
Individual
100.0%
100.0%
2021
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Neo Biopharm ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Jakob Juul Rasmussen
Management
0 companies